Form 4: Grace Therapeutics CEO Granted Stock Options

Sentiment:

SEC Form 4 Filing


Prashant Kohli, CEO of Grace Therapeutics, Inc., was granted stock options to purchase 225,400 shares of common stock at an exercise price of $2.08 on April 14, 2025, according to a Form 4 filing.

Summary

  • Prashant Kohli, the CEO of Grace Therapeutics, Inc., was granted stock options on April 14, 2025.
  • The options allow him to purchase 225,400 shares of the company's common stock.
  • The exercise price for these options is $2.08 per share.
  • The options vest quarterly over a 3-year period, contingent upon Kohli's continuous service.
  • The options expire on April 14, 2035.
  • A Power of Attorney was executed on April 8, 2025, granting Robert DelAversano, Steven Abrams, Valerie Delp and Irina Abbas the authority to act on Kohli's behalf for SEC filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice, and there's no indication of positive or negative implications for the company's performance.

Positives

  • The granting of stock options to the CEO can align his interests with those of the shareholders, incentivizing him to improve the company's performance.
  • The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders. The vesting schedule is typical for such grants.

Comparison to Industry Standards

  • Stock option grants are a common form of executive compensation across various industries, including pharmaceuticals.
  • Vesting schedules of three years are fairly standard for these types of grants.
  • Comparing the size of the grant to similar companies would require further analysis of executive compensation packages in the peer group.

Stakeholder Impact

  • Shareholders may view the stock option grant as a positive incentive for the CEO.
  • Employees may see it as a sign of confidence in the company's future.

Key Dates

DateDescription
04/08/2025Power of Attorney executed by Prashant Kohli.
04/14/2025Date of the stock option grant to Prashant Kohli.
04/16/2025Date of signature for the Form 4 filing.
04/14/2035Expiration date of the stock options.

Keywords

stock options, Form 4, Grace Therapeutics, Prashant Kohli, CEO, insider trading, beneficial ownership, securities, equity, vesting, power of attorney

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.